Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]
Proposed [GID-TA10767] Expected publication date: TBC
Search results
163 results
-
-
Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]
Proposed [GID-TA10768] Expected publication date: TBC
-
Pralsetinib for treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3875]
Proposed [GID-TA10770] Expected publication date: TBC
-
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Proposed [GID-TA10773] Expected publication date: TBC
-
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]
Proposed [GID-HST10039] Expected publication date: TBC
-
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Proposed [GID-TA10774] Expected publication date: TBC
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]
Proposed [GID-TA10775] Expected publication date: TBC
-
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Proposed [GID-TA10776] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]
Proposed [GID-TA10777] Expected publication date: TBC
-
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]
Proposed [GID-TA10778] Expected publication date: TBC
-
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Proposed [GID-TA10779] Expected publication date: TBC
-
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]
Proposed [GID-TA10715] Expected publication date: TBC
-
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]
Proposed [GID-TA10717] Expected publication date: TBC
-
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]
Proposed [GID-TA10718] Expected publication date: TBC
-
Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]
Proposed [GID-TA10332] Expected publication date: TBC
-
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154
Proposed [GID-TA10198] Expected publication date: TBC
-
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Proposed [GID-TA10336] Expected publication date: TBC
-
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)
Proposed [GID-TA10426] Expected publication date: TBC
-
Semaglutide for treating type 2 diabetes (ID1450)
Proposed [GID-TA10438] Expected publication date: TBC
-
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]
Proposed [GID-TA10297] Expected publication date: TBC
-
Pegvaliase for treating phenylketonuria [ID1110]
Proposed [GID-TA10345] Expected publication date: TBC
-
Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)
Proposed [GID-TA10239] Expected publication date: TBC
-
Rivaroxaban for treating chronic heart failure [ID1462]
Proposed [GID-TA10393] Expected publication date: TBC
-
Avalglucosidase alfa for treating Pompe disease [ID3737]
Proposed [GID-HST10030] Expected publication date: TBC
-
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
Proposed [GID-HST10037] Expected publication date: TBC
-
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587
Proposed [GID-TA10519] Expected publication date: TBC
-
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 05 March 2021.
-
Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF Review of TA492) ID3777
Proposed [GID-TA10810] Expected publication date: 22 October 2021
-
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]
Proposed [GID-TA10453] Expected publication date: TBC
-
Dulaglutide for treating type 2 diabetes [ID1451]
Proposed [GID-TA10439] Expected publication date: TBC
-
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Proposed [GID-TA10553] Expected publication date: TBC
-
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)
Proposed [GID-TA10306] Expected publication date: TBC
-
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]
Proposed [GID-TA10802] Expected publication date: TBC
-
Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]
Proposed [GID-TA10803] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab or a taxane [ID3909]
Proposed [GID-TA10804] Expected publication date: TBC
-
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]
Proposed [GID-TA10788] Expected publication date: TBC
-
Timrepigene emparvovec for treating choroideremia [ID3916]
Proposed [GID-TA10787] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]
Proposed [GID-TA10786] Expected publication date: TBC
-
Polatuzumab vedotin with R-CHP for untreated diffuse large B-cell lymphoma [ID3901 ]
Proposed [GID-TA10785] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]
Proposed [GID-TA10784] Expected publication date: TBC
-
Pegunigalsidase alfa for treating Fabry disease [ID3904]
Proposed [GID-TA10790] Expected publication date: TBC
-
Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]
Proposed [GID-TA10789] Expected publication date: TBC
-
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]
Proposed [GID-TA10783] Expected publication date: TBC
-
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]
Proposed [GID-TA10791] Expected publication date: TBC
-
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]
Proposed [GID-TA10795] Expected publication date: TBC
-
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]
Proposed [GID-TA10792] Expected publication date: TBC
-
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]
Proposed [GID-TA10796] Expected publication date: TBC
-
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]
Proposed [GID-TA10793] Expected publication date: TBC
-
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]
Proposed [GID-TA10797] Expected publication date: TBC
-
Brolucizumab for treating diabetic macular oedema [ID3902]
Proposed [GID-TA10794] Expected publication date: TBC